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Abstract: Rapid new microvascular network induction was critical for bone regeneration, which
required the spatiotemporal delivery of growth factors and transplantation of endothelial cells. In
this study, the linear poly(D,L-lactic-co-glycolic acid)-b-methoxy poly(ethylene glycol) (PLGA-mPEG)
block copolymer microspheres were prepared for simultaneously delivering vascular endothelial
growth factor (VEGF) and monocyte chemotactic protein-1 (MCP-1). Then, vascular endothelial cells
(VECs) with growth factor loaded microspheres were composited into a star-shaped PLGA-mPEG
block copolymer solution. After this, composite hydrogel (microspheres ratio: 5 wt%) was formed
by increasing the temperature to 37 ◦C. The release profiles of VEGF and MCP-1 from composite
hydrogels in 30 days were investigated to confirm the different simultaneous delivery systems. The
VECs exhibited a good proliferation in the composite hydrogels, which proved that the composite
hydrogels had a good cytocompatibility. Furthermore, in vivo animal experiments showed that the
vessel density and the mean vessel diameters increased over weeks after the composite hydrogels
were implanted into the necrosis site of the rabbit femoral head. The above results suggested that the
VECs-laden hydrogel composited with the dual-growth factor simultaneous release system has the
potential to enhance angiogenesis in bone tissue engineering.
Keywords: composite hydrogel; simultaneous release; growth factor; angiogenesis; bone
tissue engineering
1. Introduction
There was an urgent need of engineered-organ transplantation for treating bone-related diseases,
such as the bone tumor, osteoporosis, and osteonecrosis of the femoral head (ONFH). The temporary
three-dimensional (3D) multifunctional scaffold has the potential to induce physiological regeneration,
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including angiogenesis and osteogenesis [1–4]. Thereinto, the ingrowth of new blood vessels was
critical for stimulating osteogenesis, and the formed capillary network also served as a template
for new bone formation [5]. The lack of microvasculature formation remains a key roadblock to
apply engineered composites to clinical applications up to now [6]. Several reports proved that
many soluble growth factors could regulate vasculogenesis and angiogenesis, mainly including the
vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), insulin-like growth factor
(IGF), hepatocyte growth factor (HGF), platelet-derived growth factor-BB (PDGF-BB), monocyte
chemoattractant protein-1 (MCP-1), etc. [7–11]. VEGF was one of the most important growth factors
across all stages of neovascularization, mainly through initiating the sprouting of existing blood
vessels by mitogenic and chemotactic effects, and facilitating the recruitment of circulating endothelial
progenitor cells [9,10]. Furthermore, VEGF was also important for maintaining the survival of blood
vessels, the data indicated that the withdrawal of VEGF caused vascular collapse and regression [9–11].
As a matter of fact, a sustaining release of VEGF at least for a period of four weeks could improve
the maturing and stabilizing of newly formed blood vessels [12]. On the other hand, the VEGF could
not only stimulate the proliferation, migration, and survival of VECs, but also enhanced the alkaline
phosphatase activity, mineralized tissue production, and adhered molecule, which played an important
role in fracture healing [13,14]. Because of its short half-life and enzymatic degradation of the growth
factors, some side effects were unavoidable by using very high doses. Thus, an effective delivery
system was significant.
On the other hand, new bone formation and angiogenesis were intimately connected during tissue
regeneration [5]. Many studies confirmed that bone tissue regeneration could be ameliorated via the
spatiotemporal release of VEGF and bone growth factors, for instance, bone morphogenetic protein-2
(BMP-2) [15–17]. MCP-1, known as chemokine (C-C motif) ligand 2 (CCL2), was an arteriogenic factor
that could induce a remarkable host vascularization response at an early stage, and it was clear that
the dual delivery of MCP-1 and VEGF induced the mural cell recruitment and improved survival
of endothelial cells (ECs) [4]. In addition, it has been shown that early-stage growth factors could
have synergy effects on late-stage factors and vice versa when presented simultaneously [18]. In our
previous reports, the biodegradable block copolymer microspheres were proven to be an effective
delivery vehicle for encapsulation and the controlled release of growth factors [19,20]. The release
profile of the growth factor from microspheres could be regulated by adjusting the degradability rate
of microspheres. Therefore, a different simultaneous delivery system of dual-growth factors could be
facilely constructed through compositing different growth factor loaded microspheres together [21,22].
It was also shown that the injectable hydrogel composited with the delivery system has the potential for
treating early-stage osteonecrosis of the femoral head, and such an injection treatment performed many
advantages compared to traditional engineered scaffold replacement, including surgical convenience,
and lower side effects, etc. [23–27].
In this work, VEGF and MCP-1 were loaded into different linear poly(D,L-lactic-co-glycolic
acid)-b-methoxy poly(ethylene glycol) (PLGA-mPEG) block copolymer microspheres with different
[LA]/[GA] ratios respectively. Then, the growth factors loaded microspheres were composited with
star-shaped PLGA-mPEG block copolymer solution, after that, the composite hydrogel was obtained
via adjusting the temperature to 37 ◦C. According to the formulation of microspheres in hydrogels,
different delivery systems were designed. At the same time, the vascular endothelial cells (VECs)
were also loaded into composite hydrogel during the hydrogel formation process (Figure 1). The
release profiles of VEGF and MCP-1 were investigated by ELISA kits, the proliferation of VECs in
composite hydrogels was also evaluated. Finally, vascularization followed by new bone formation
was investigated via in vivo animal experiments.
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Figure 1. The schematic illustration for the preparation of composite hydrogel by using the VEGF and 
MCP-1 simultaneous delivery system (different release profiles of growth factor depend on time) and 
encapsulating VECs. Different microspheres loaded with VEGF and MCP-1 were composited into a 
star-shaped block copolymer solution (using simulation body fluid), at the same time, VECs were 
added into, then cells-laden composite hydrogel was formed at 37 °C. (a) VEGF and MCP-1 release 
profiles from delivery system I; (b) VEGF and MCP-1 release profiles from delivery system II; (c) 
MCP-1 and VEGF release profiles from delivery system III. 
2. Materials and Methods  
2.1. Materials 
D,L-lactide (LA), glycolide (GA), monomethoxy poly(ethylene glycol) (mPEG, Mn = 550), and 
stannous octoate (Sn(Oct)2) were purchased from Sigma Chemical Co. Ltd. (Poole, U.K.). VEGF was 
obtained from ThermoFisher Scientific Co., Ltd. (Shanghai, China), MCP-1 was obtained from Sino 
Biological Co., Ltd. (Shanghai, China), and ELISA kits for VEGF and MCP-1 were purchased from 
Peprotech (Rocky Hill, NJ). All other chemicals were purchased from China National Medicines 
Corporation Ltd. (analytical grade). 
2.2. Microspheres Preparation 
The linear PLGA-mPEG block copolymers (PLGA1320-mPEG550 copolymer with an [LA]/[GA] 
ratio of 1, designated as CP-1, and P(LA3GA)1320-mPEG550 copolymer with an [LA]/[GA] ratio of 3, 
designated as CP-2) were synthesized (Supplementary Materials) [24]. The VEGF and MCP-1 loaded 
CP-1 microspheres, VEGF loaded CP-1 microspheres, MCP-1 loaded CP-1 microspheres, VEGF 
loaded CP-2 microspheres, and MCP-1 loaded microspheres were fabricated by using a double-
Figure 1. The schematic illustration for the pre aration f c mposite hydrogel by using the VEGF and
MCP-1 simultaneous delivery system (different release profiles of growth factor depend on time) and
encapsulating VECs. Different microspheres loade with VEGF and MCP-1 were composited into
a star-shaped block copolymer solution (using simulation body fluid), at the same time, VECs were
added into, then cells-laden composite hydrogel was formed at 37 ◦C. (a) VEGF and MCP-1 release
profiles from delivery system I; (b) VEGF and MCP-1 release profiles from delivery system II; (c) MCP-1
and VEGF release profiles from delivery system III.
2. Materials and Methods
2.1. Materials
D,L-lactide (LA), glycolide (GA), monomethoxy poly(ethylene glycol) (mPEG, Mn = 550), and
stannous octoate (Sn(Oct)2) were purchased from Sigma Chemical Co. Ltd. (Poole, U.K.). VEGF
was obtained from ThermoFisher Scientific Co., Ltd. (Shanghai, China), MCP-1 was obtained from
Sino Biological Co., Ltd. (Shanghai, China), and ELISA kits for VEGF and MCP-1 were purchased
from Peprotech (Rocky Hill, NJ). All other chemicals were purchased from China National Medicines
Corporation Ltd. (analytical grade).
2.2. Microspheres Preparation
The linear PLGA-mPEG block copolymers (PLGA1320-mPEG550 copolymer with an [LA]/[GA]
ratio of 1, designated as CP-1, and P(LA3GA)1320-m E 550 copolymer with an [LA]/[GA] ratio of
3, designated as CP-2) were synthesized (Supplementary Materials) [24]. The VEGF and MCP-1
loa d CP-1 microspher s, VEGF loa ed CP-1 icrospheres, MCP-1 loaded CP-1 microspheres,
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VEGF loaded CP-2 microspheres, and MCP-1 loaded microspheres were fabricated by using a
double-emulsion method according to our previous works (Supplementary Materials) [20]. The
morphology of microspheres was examined by Cold Field Scanning Electron Microscopy (SEM, S4800).
2.3. Composite Hydrogels Preparation
The star-shaped PLGA-mPEG block copolymer (star-P(LA3GA)1320-mPEG550 with an [LA]/[GA]
ratio of 3) was synthesized (Supplementary Materials) [24]. The prepared star-shaped block copolymer
was dissolved into simulation body fluid (40 wt%) to obtain a copolymer solution at 10–20 ◦C, then the
prepared growth factors loaded microspheres were added into copolymer solution, next, the composite
hydrogels were produced at 37 ◦C. In this paper, three delivery systems were designed (Figure 1, Table
S1). The release profiles of VEGF and MCP-1 were tested by ELISA kits.
2.4. In Vitro Cytocompatibility
VECs (obtained from ATCC® CRL-4053TM) were grown in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum, 100 U mL−1 penicillin, and 100 µg mL−1
streptomycin (all purchased from Gibco, Invitrogen, N.Y., USA) under a humidified atmosphere of 5%
CO2 at 37 ◦C. During the composite hydrogel preparation, VECs and microspheres were composited to
obtain the VECs-laden composite hydrogel. The VECs viability in composite hydrogels at the different
days was characterized by using a CCK-8 assay. At the same time, the VECs-laden composite hydrogels
were removed from the culture media after 3 days, the phalloidin-FITC (50 µg/mL, Invitrogen, N.Y.,
USA) and 4,6-diamidino-2-phenylindole (DAPI, 10 µg/mL, Invitrogen, NY, USA) were used to stainf
the VECs to investigate the proliferation of the VECs; the pink color was used to indicate cytoskeleton,
the blue color was used to indicate the nucleus (Supplementary Materials).
2.5. In Vivo Studies
2.5.1. Animal Experiments
Based on the microstructure, composition, and remodeling of rabbit bones, rabbits showed
many advantages for bone regeneration experiments [28,29]. The Japanese rabbits were used in
this study. For all studies, rabbits were anesthetized with 2% pentobarbital sodium (30 mg/kg) via
the rabbit ear marginal vein, and the animals were kept in the Institute of Experimental Animals of
Wuhan Hanyang Hospital, in accordance with the institutional guidelines for care and use of laboratory
animals. The animal experiments were approved by the Animal Ethical Committee of Wuhan Hanyang
Hospital (Permit number 00027467). The femoral head necrosis model in the right-posterior position
of rabbits was constructed firstly, then the star-shaped block copolymer solution composited with
VECs and growth factor loaded microspheres were injected into necrosis site, the composite hydrogel
was formed inside in 5 min. The rabbits were treated at week 4 and 8 for angiogenesis evaluations
(Supplementary Materials).
2.5.2. X-Ray Scanning
After the surgery, X-ray scanning of the rabbit femoral head in the right-posterior position was
performed using an X-ray machine (Digital Diagnosis, Philips, Amsterdam, The Netherlands). The
X-ray radiographs reflected the soft tissue swelling around the femoral head, osteolysis, deformity,
and osteogenesis at necrosis sites.
2.5.3. Histological Analysis
After X-ray scanning, the rabbits were sacrificed at weeks 4 and 8 post-surgery, and the biopsies
of implants and the adjacent tissues were obtained. Then the biopsies and tissues were fixed in
formalin and embedded in paraffin for H&E and Masson’s Trichrome staining. The histological
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analysis combined with X-ray at the same necrosis site was used to investigate vascularization. The
vessel density and mean vessel diameter were quantitatively analyzed by using ImageJ software.
2.6. Statistical Analysis
Unless indicated, data were given as mean ± SD (n = 5). Statistics analysis of obtained results
was carried out using a one-way analysis of variance (one-way ANOVA), and significance reported at
a p-value of <0.05 for 95% confidence. All statistical calculations were performed using the GraphPad
Prism software.
3. Results
3.1. Release Delivery of VEGF and MCP-1
The VEGF and MCP-1 loaded CP-1 microspheres, VEGF loaded CP-1 microspheres, MCP-1 loaded
CP-1 microspheres, VEGF loaded CP-2 microspheres, and MCP-1 loaded microspheres were prepared
by a double emulsion method. SEM images showed that growth factors loaded microspheres were
homogeneous and the diameters for the different kind of microspheres were 0.7 ± 0.12 µm (Figure S1).
Then, the growth factor encapsulation efficiency (Eencaps) was measured using ELISA kits, as shown in
Figure S2. For dual VEGF and MCP-1 loaded into CP-1 or CP-2 microspheres, the Eencaps of MCP-1 was
higher than that of VEGF, and for a single growth factor loaded into CP-1 or CP-2 microspheres, the
Eencaps of MCP-1 was also higher than that of VEGF. According to the Eencaps of VEGF and MCP-1, and
the biodegradable characteristics of linear PLGA-mPEG block copolymer microspheres, three delivery
systems were constructed by allocating different types of microspheres into star-shaped PLGA-mPEG
hydrogels (Figure 1) [19]. Figure 1a showed that VEGF and MCP-1 had a similar release profile from
the composite hydrogel in 4 weeks, proved that VEGF and MCP-1 were simultaneously released
from the hydrogel. However, the cumulative MCP-1 release in delivery system II increased fast to
49.3 ± 4.7% within the first 9 days compared to the delivery system I (36.7± 3.1%), exhibiting an initial
burst release behavior (Figure 1b). For delivery system III, the cumulative MCP-1 release decreased
to 16.8 ± 3.9%, presenting a delayed release behavior (Figure 1c). Meanwhile, VEGF performed a
delay-release profile in delivery system II, which was similar to release profile of MCP-1 in delivery
system III.
3.2. In Vitro Cell Viability
The VECs viability in composite hydrogels was quantitatively investigated by a CCK-8 assay
(Figure S3). The result showed that VECs viability increased over days in composite hydrogels with
different delivery systems. Furthermore, VECs proliferated at a higher rate in the circumstance of
delivery system II compared to others. The growth factor loaded microspheres dispersed in hydrogels
uniformly which was confirmed by an optical microscope images analysis, and VECs expressed a
formless morphology in composite hydrogels based on the fact that VECs could grow and reproduce
in three-dimensional (3D) environments (Figure 2a–c). Fluorescence assay (DAPI/FITC) was also
performed to evaluate the VECs proliferation in composite hydrogels, and the results were shown in
Figure 2d–f where the cytoskeleton was represented by blue color and the nucleus was represented
by blue color. Results displayed that the number of VECs in delivery system II and III was relatively
higher than that of delivery system I.
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Figure 2. The VECs proliferation while cultured with composite hydrogels with different delivery 
systems at day 3. Optical microscope images of VECs in composite hydrogels with (a) delivery system 
I, (b) delivery system II, and (c) delivery system III. Meanwhile, the fluorescence images of VECs were 
obtained with (d) delivery system I, (e) delivery system II, and (f) delivery system III. The cell nucleus 
was represented by blue color, and cytoskeleton was represented by pink color. Scale bar: 25 μm. 
3.3. In Vivo Animal Study 
VECs-laden composite hydrogels with different delivery systems were implanted into necrosis 
site of femur head in Japanese rabbits by injection, all rabbits resumed normal ambulation and daily 
activity within one or two days after surgery. No signs of infection and wound split, and appetite 
loss was not observed for rabbits. Firstly, the host reaction around tissues and bone regeneration were 
evaluated by X-ray scanning and histological images, the results were presented in Figures 3 and 4. 
Figure 3a–d confirmed the successful construction of a femur head necrosis model by using the 
anhydrous alcohol method within 3 weeks. Soft tissue swelling around femur head was found before 
injection, and such swelling vanished after 4 weeks. The necrosis site couldn’t be self-healed without 
intervention. However, new bone tissue was observed at the necrosis site with composite hydrogels 
treatment since week 4, and new bone tissue was filled up at necrosis site completely at week 8. The 
vessels density and mean vessel diameter were quantitatively obtained by ImageJ software according 
to H&E and Masson staining results (20 images for each sample, which is the same necrosis site for 
the X-ray image), and the results were shown in Figure 5. The vessels density and mean vessel 
diameter in composite hydrogels with different delivery systems increased over the weeks compared 
to the control group. At week 4, the rabbits treated by composite hydrogel with delivery system II 
showed the highest value of the mean vessel diameter. However, at week 8, the highest data of the 
vessel density and mean vessel diameter were observed in the delivery system III group. H&E and 
Masson staining results confirmed that the new blood vessels were formed at the necrosis site of the 
rabbit femur head and that the ingrowth of new bone tissue was consistent with cell vessels density 
and mean vessel diameter. 
Figure 2. The VECs proliferation while cultured with composite hydrogels with different delivery
systems at day 3. Optical microscope images of VECs in composite hydrogels with (a) delivery system
I, (b) delivery system II, and (c) delivery system III. Meanwhile, the fluorescence images of VECs were
obtained with (d) delivery system I, (e) delivery system II, and (f) delivery system III. The cell nucleus
was represented by blue color, and cytoskeleton was represented by pink color. Scale bar: 25 µm.
3.3. In Vivo Animal Study
VECs-laden composite hydrogels with different delivery systems were implanted into necrosis
site of femur head in Japanes rabbits by injection, all rabbits resumed normal a bula ion and daily
activity within one or two days after surgery. No signs of infection an wound split, nd appetite
loss was not observ d for rabbits. Firstly, the host reaction around tissues and bone regeneration
were evaluated y X-ray scanning and histological images, the result were presented i Figures 3
and 4. Figure 3a–d confirmed the succe sful construction of a f mur head necrosis model by using the
anhydrous lcoh l method within 3 weeks. Sof tissue swelling around femur head was found before
injection, and such swelling van s ed aft r 4 weeks. Th necrosis site couldn’t be self-he led without
intervention. However, new bone tissue was obs rved at the necrosis site with composit hy rogels
treatment since week 4, and new bone tissue was filled up a necrosis site completely at we k 8. The
vess ls d sity and m an vessel diameter were qu ntitatively obtained by ImageJ software according
to H&E an Masso staining r ults (20 images for each sample, which is the same necrosis site for the
X-ray image), and the results we shown in Fi ure 5. The vessels density and mean vessel diame r
in composite hydrogels with different delivery systems increased over the w eks compared to the
control group. At week 4, the rabbits treated by composite hydrogel with delivery system II showed
the highest value of the mean vessel diameter. However, at week 8, the highest data of the vessel
density and mean v ssel diameter were observed in the delivery system III group. H&E and Masson
staining results co fir d that the new blood v ssels w re forme at the necrosis site f the rabbit
femur head nd that the ingrowth of new bo tissue was consistent with cell vessels density and
me n vessel diameter.
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Figure 3. The X-ray images of the rabbit femur head in the right-posterior position at 4th and 8th 
weeks post-operation. The femoral head necrosis models were constructed by using the bone injection 
of anhydrous alcohol method (a–d), the circles indicated the necrosis district. Non-intervention 
treatment as a control group, images (e, i) showed femur head without treatment (control group) at 
4th and 8th weeks respectively; images (f, j) showed femur head treated by composite hydrogel with 
delivery system I at 4th and 8th weeks respectively; images (g, k) showed femur head treated by 
composite hydrogel with delivery system II at 4th and 8th weeks respectively; images (h, l) showed 
femur head treated by composite hydrogel with delivery system III at 4th and 8th weeks, respectively. 
Scale bar: 1 cm, the arrows indicated the regeneration district. 
Figure 3. The X-ray images of the rabbit femur head in the right-posterior position at 4th and 8th weeks
post-operation. The femoral head necrosis models were constructed by using the bone injection of
anhydrous alcohol method (a–d), the circles indicated the necrosis district. Non-intervention treatment
as a control group, images (e,i) showed femur head without treatment (control group) at 4th and
8th weeks respectively; images (f,j) showed femur head treated by composite hydrogel with delivery
system I at 4th and 8th weeks respectively; images (g,k) showed femur head treated by composite
hydrogel with delivery system II at 4th and 8th weeks respectively; images (h,l) showed femur head
treated by composite hydrogel with delivery system III at 4th and 8th weeks, respectively. Scale bar: 1
cm, the arrows indicated the regeneration district.
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Figure 4. The representative optical images of H&E and Masson staining slices of cross sections at the 
necrosis site where the composite hydrogels were implanted at the 4th and 8th weeks. (a, c) Control 
groups without intervention at 4th weeks; (b, d) control groups without intervention at 8th weeks; (e, 
g) the necrosis site treated by using composite hydrogels with delivery system I at 4th week; (f, h) the 
necrosis site treated by using composite hydrogels with delivery system I at the 8th week; (i, k) the 
necrosis site treated by using composite hydrogels with delivery system II at the 4th week; (j, l) the 
necrosis site treated by using composite hydrogels with delivery system II at the 8th week; (m, o) the 
necrosis site treated by using composite hydrogels with delivery system III at the 4th week; (n, p) the 
necrosis site treated by using composite hydrogels with delivery system III at the 8th week. Scale bar: 
100 μm. 
Figure 4. The representative optical images of H&E and Masson staining slices of cross sections at the
necrosis site where the composite hydrogels were implanted at the 4th and 8th weeks. (a,c) Control
groups without intervention at 4th weeks; (b,d) control groups without intervention at 8th weeks;
(e,g) the necrosis site treated by using composite hydrogels with delivery system I at 4th week; (f,h) the
necrosis site treated by using composite hydrogels with delivery system I at the 8th week; (i,k) the
necrosis site treated by using composite hydrogels with delivery system II at the 4th week; (j,l) the
necrosis site treated by using composite hydrogels with delivery system II at the 8th week; (m,o) the
necrosis site treated by using composite hydrogels with delivery system III at the 4th week; (n,p) the
necrosis site treated by using composite hydrogels with delivery system III at the 8th week. Scale bar:
100 µm.
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Figure 5. The vessels density and mean vessel diameter were analyzed by the ImageJ software 
quantitatively according to H&E and Masson stained slices after the implantation of the composite 
hydrogels with different delivery systems into the necrosis site of femur head in rabbits at the 4th and 
8th weeks. (a) Vessels density increased over weeks for three delivery systems; (b) mean vessel 
diameter also increased over weeks for three delivery systems, and delivery system III showed the 
highest value at the 4th week. Non-intervention treatment as a control group (*** p < 0.001, * p < 0.05). 
4. Discussion 
New vessels could be formed via the sprouting of existing vessels (angiogenesis) or the 
development of de novo vessels from progenitor cells (vasculogenesis), and during these complex 
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matrix (ECM) components could regulate both a nascent tube formation and vessel maturation 
[30,31]. The 3D scaffold encapsulated with cells and dual growth factors delivery system could mimic 
the natural microenvironment for vascularization and new bone formation in bone tissue 
engineering. Traditional growth factor administration caused high toxicity because of short half-lives 
of growth factor and slow penetration into tissue. Recently, the polymer microspheres have been 
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copolymer microspheres had practical advantages on loading growth factor. For instance, the 
encapsulation efficiency could be regulated by the size of the microspheres, and release profile of 
growth factor could be adjusted by [LA]/[GA] ratio [19–21]. In this work, two linear PLGA-mPEG 
block copolymers with a different [LA]/[GA] ratio (CP-1, CP-2) were used to prepare microspheres, 
the uniform growth factor loaded microspheres were obtained by the double emulsion method. The 
encapsulation efficiency of MCP-1 showed a higher value into CP-1 and CP-2 microspheres than that 
of VEGF (Figure S2). A higher initial loading with respect to the microspheres compared to the 
previous report (MCP-1, 1200 ng/mg; VEGF, 1200 ng/mg) was operated in this study, thus the release 
of both growth factors could remain for 4 weeks at least. While the growth factor loaded microspheres 
were composited into the hydrogel, the release of the growth factor was a little delayed from 
composite hydrogel compared to the bare microspheres [23,32]. However, the release profile of 
growth factor was mainly controlled by the degradability rate of the microspheres, thus different 
delivery systems could be facilely constructed by designing the proper formulation of microspheres 
co-loaded with VEGF and MCP-1, VEGF loaded microsphere, and MCP-1 loaded microsphere in 
hydrogels (Figure 1).  
On the other hand, VECs transplantation was an effective approach for vascularization [4], and 
our previous works have proved that composite hydrogel encapsulated with VECs could enhance 
new blood vessel formation [23]. In this paper, both the linear PLGA-mPEG block copolymer for 
microsphere preparation and star-shaped PLGA-mPEG block copolymer for hydrogel preparation 
possessed a good cytocompatibility, thus, VECs survived in the composite hydrogel, and the viability 
Figure 5. The vessels density and mean vessel diameter were analyzed by the ImageJ software
quantitatively according to H&E and Masson stained slices after the implantation of the composite
hydrogels with different delivery systems into the necrosis site of femur head in rabbits at the 4th
and 8th weeks. (a) Vessels density increased over weeks for three delivery systems; (b) mean vessel
diameter also increased over weeks for three delivery systems, and delivery system III showed the
highest value at the 4th week. Non-intervention treatment as a control group (*** p < 0.001, * p < 0.05).
4. Discussion
New vessels could be formed via the sprouting of existing vessels (angiogenesis) or the
development of de novo vessels from progenitor cells (vasculoge esis), and during these complex
processes, the suitable microenviron ent which consists of cells, growth factors, and extracellular
matrix (ECM) components could regulate both a nascent tube formation and vessel maturation [30,31].
The 3D scaffold encapsulated with cells and dual growth factors delivery system could imic the
natural microenvironme t for vascularization an new bone formation in bone tissue engineering.
Traditional growth factor administration caused high toxicity because of short half-lives f growth
factor and slow penetration into tissue. Recently, the polymer microspheres have been widely
used for growth factor storage and delivery efficiency. Our previous works showed that the linear
poly(D,L-lactic-co-glycolic acid)-b-methoxy poly(ethylene gl col) (PLGA-mPEG) block copolymer
microspheres had practical advantages on loading growth factor. For instance, the encapsulati n
efficiency could be regulated by the size of the microspheres, and release profile of growth factor could
be adjusted by [LA]/[GA] ratio [19–21]. In this work, two linear PLGA-mPEG block copolymers with
a different [LA]/[GA] ratio (CP-1, CP-2) were used to prepare microspheres, the uniform growth factor
loaded microspheres were obtai ed by the double emulsion method. The encapsulation efficiency
of MCP-1 showed a higher value into CP-1 and CP-2 microspheres than that of VEGF (Figure S2).
A higher initial loadi g with respect to the microspheres compared to the previous report (MCP-1,
1200 ng/mg; VEGF, 1200 ng/mg) was operated in this study, thus the release of both growth factors
could remain for 4 weeks at least. While the growth factor loaded microspheres were composited into
the hydrogel, the release of the growth factor was a little delayed from composite hydrogel compared
to the bare microspheres [23,32]. However, the release profile of growth factor was mainly controlled by
the degradability rate of the microspheres, thus different delivery systems could be facilely constructed
by designing the proper formulation of microspheres co-loaded with VEGF and MCP-1, VEGF loaded
microsphere, and MCP-1 loaded microsphere in hydrogels (Figure 1).
On the other hand, VECs transplantation was an effective approach for vascularization [4], and
our previous works have proved that composite hydrogel encapsulated with VECs could enhance
new blood vessel formation [23]. In this paper, both the linear PLGA-mPEG block copolymer for
microsphere preparation and star-shaped PLGA-mPEG block copolymer for hydrogel preparation
possessed a good cytocompatibility, thus, VECs survived in the composite hydrogel, and the viability
of VECs also increased over days (Figure 2 and Figure S3). The growth factors alone could not promote
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the formation of the stable vasculature. So, it was a promising strategy to develop vascularization
via the incorporation of VECs into composite hydrogel [33]. Cell-based approaches for therapeutic
vascularization, including endothelial progenitor cell delivery, the engineered mesenchymal cell-based
patches, and macrophage-based therapeutic strategies, have been studied for many years. However,
many VECs-based approaches could not work effectively in clinical trials, which was not surprising
as they lacked the proper delivery system of multiple growth factors due to the failure of recruiting
and transplanting VECs [34,35]. Here, the synergistic effects of VECs and different simultaneous
delivery systems of VEGF and MCP-1 on new vessel formation were primarily evaluated through
in vivo animal experiments.
The star-shaped PLGA-mPEG block copolymer solution with an incorporation of the delivery
system and VECs could be injected into a necrosis site of the femur head in Japanese rabbit. The
composite hydrogel was formed in time with the help of animal body temperature. This technique
was not only operated easily by researchers compared to traditional engineered scaffold replacement
but also provided a new therapeutic strategy for treating chronic femoral head necrosis at an early
stage instead of a total hip replacement [23,27]. Being benefited from the good histocompatibility
of the composite (Figure 4), the composite hydrogel treatment did not affect the bodily functions of
rabbits, and abnormal signs such as infection, host reaction were not detected. On the other hand, in
the clinic, although magnetic resonance imaging showed many advantages at an early stage compared
to X-rays, such as a high image quality, considering the lost-cost of the X-rays for patients, X-ray
combined with a histological analysis were used in this study [36]. We previously explored the effect
of the sustained release of VEGF on vessel formation [23]. In this study, we expanded single VEGF to
the simultaneous release of VEGF and MCP-1. MCP-1 showed a distinct behavior in three delivery
systems, thus, leading to observable differences at different delivery systems (* p < 0.05), and significant
differences compared to control group without intervention (*** p < 0.001). So, the release profile of
MCP-1 played an important role in new vessel formation [7]. At week 8, the vessel density and mean
average diameter of vessels both increased. The data showed that the simultaneous release of VEGF
and MCP-1 promoted mature vessels formation in comparison to a single VEGF release. Although new
bones have emerged, some old bones and necrotic bones might still exist, above phenomena might
cause the resurgence of diseases, and then increased second surgical risk. Thus, the sequential delivery
of multiple growth factors still needs to be explored in the future. In addition, besides VECs, other
types of cells such as stem cells and macrophages need to be loaded into composites with multiple
growth factors delivery system for angiogenesis and osteogenesis for bone regeneration [34,35,37].
5. Conclusions
In summary, the simultaneous delivery system for releasing VEGF and MCP-1 could be facilely
constructed by using a linear PLGA-mPEG block copolymer microspheres carrier. The composited
delivery system with VECs into star-shaped PLGA-mPEG block copolymer hydrogel; VECs showed
a good proliferation in the composite hydrogel. Finally, the composite hydrogel was implanted into
a necrosis site of rabbit femoral head by injection, the vessels density and mean vessels diameters
increased over weeks which were confirmed by histological analysis. The present works advised
that the simultaneous release of the VEGF and MCP-1 composite with VECs in hydrogels provided a
potential strategy for therapeutic vascularization in bone tissue engineering. However, this strategy
still bears further pre-clinical exploration in models of bone-related diseases.
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images of VEGF and/or MCP-1 loaded CP-1 and CP-2 microspheres, Figure S2: The encapsulation efficiency of
VEGF and/or MCP-1 in CP-1 and CP-2 microspheres, Figure S3: CCK-8 assay of VECs cultured with composite
hydrogels for 1, 3 and 5 days.
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